Drug Profile
Anifrolumab - AstraZeneca
Alternative Names: Anifrolumab-fnia - AstraZeneca; Anti-IFNaR MAb - AstraZeneca; MDX-1333; MEDI-546; SAPHNELO; SaphneloLatest Information Update: 29 Dec 2023
Price :
$50
*
At a glance
- Originator Medarex
- Developer AstraZeneca; Medarex; MedImmune
- Class Antirheumatics; Monoclonal antibodies; Skin disorder therapies; Urologics
- Mechanism of Action Interferon alpha beta receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Systemic lupus erythematosus
- Phase III Lupus nephritis; Scleroderma
- Phase II Sjogren's syndrome
- Discontinued Rheumatoid arthritis
Most Recent Events
- 10 Nov 2023 Efficacy data from a phase III TULIP SLE LTE trial in Systemic lupus erythematosus presented at ACR Convergence 2023
- 08 Nov 2023 Phase-III clinical trials in Scleroderma (In adults, In the elderly) in Poland, United Kingdom, Spain, USA (SC) (NCT05925803)
- 29 Jun 2023 AstraZeneca plans the DAISY phase III trial for Systemic scleroderma (In adults, In the elderly) in USA, Austria, Belgium, Canada, China, France, Germany, Hungary, Israel, Italy, Japan, South Korea, Mexico, Netherlands, Poland, Romania, Spain, Turkey and UK (SC, Injection) (NCT05925803) (EudraCT2023-505976-31)